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Background: Recently it was shown that the oncogenic activation of BRAF, a member of the
RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon
tumours with microsatellite instability. Further, it was shown to associate with the silencing of
the mismatch repair (MMR) gene MLH1 by hypermethylation. Moreover, BRAF mutations
proved to be absent in tumours from hereditary nonpolyposis colorectal cancer syndrome
(HNPCC) families with germline mutations in the MMR genes MLH1 and MSH2. These data
suggest that the oncogenic activation of BRAF is involved only in sporadic colorectal
tumorigenesis. In order to further support this hypothesis, we have extended the analysis of
the BRAF gene to a different subset of HNPCC families without germline mutations in MLH1
and MSH2. Methods: BRAF-V600E mutations were analysed by automatic sequencing in 38
tumours from HNPCC families with germline mutations in the MSH6 gene and also in
HNPCC (suspected) families that do not have mutations in the MMR genes MLH1, MSH2
and MSH6. All patients belong to different families. Results: No mutations were detected in
14 tumours from HNPCC patients with germline mutations in MSH6. Further, no mutations of
BRAF were found in tumours from 23 MMR negative families, from which 13 fulfilled the
Amsterdam criteria (HNPCC) and 10 were suspected for HNPCC as they were positive for
the Bethesda criteria. Conclusion: Overall, our data reinforce the concept that BRAF is not
involved in the colorectal tumorigenesis of HNPCC. The detection of a positive BRAF-
V600E mutation in a colorectal cancer suggests a sporadic origin of the disease and the
absence of germline alterations of MLH1, MSH2 and also of MSH6. These findings have a
potential impact in the genetic testing for HNPCC diagnostics and suggest a potential use of
BRAF as exclusion criterion for HNPCC or as a molecular marker of sporadic cancer.
INTRODUCTION
Activation of the RAS/RAF pathway is the most common oncogenic event in colorectal
tumorigenesis. In addition to mutations in KRAS, a V600E hotspot mutation in the exon 15 of
BRAF, a member of the RAF family of kinases, has been recently reported in colorectal
tumours with high microsatellite instability (MSI-H) and was found associated to a defective
mismatch repair (MMR) system.1-3 Further, it was shown that the BRAF-V600E mutation
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(previously named V599E) is mainly found in proximal colorectal tumours in which the MSI-
H phenotype is caused by hypermethylation of the MMR gene MLH1.4,5 Tumours arising in
the hereditary nonpolyposis colorectal cancer syndrome (HNPCC) are preferentially found in
the proximal colon and show MSI due to germline defects in genes from the MMR system,
mainly MLH1, MSH2 and MSH6.6,7 Therefore, mutations in BRAF, as an alternative
oncogenic event to KRAS activation, were expected to play a role in the tumorigenesis of
HNPCC. However, recent data have provided evidence that BRAF is not involved in tumours
from HNPCC patients with germline mutations in MLH1 and MSH2, suggesting that the
oncogenic capability of BRAF in MSI colon cancer might be somehow related to the
epigenetic mechanisms involved in the inactivation of the MLH1 gene and not to the germline
MMR defect.4,8,9 Owing to its absence in the MLH1 and MSH2 germline mutation-positive
families, a potential use of BRAF-V600E in the molecular diagnostics of HNPCC has been
suggested.8,9 Nonetheless, approximately 5% of cases show germline mutations in the MSH6
gene and about half of all families clinically defined as HNPCC do not have mutations in any
of the known MMR genes, and for these cases it is yet not known whether BRAF-V600E
might play a role in tumorigenesis.7,10-12 Here we report data that support the hypothesis that
BRAF is not involved in the tumorigenesis of the HNPCC-related tumours considering
HNPCC as diagnosed on both molecular, by the presence of a germline mutation in a MMR
gene, or on clinical ground, fulfilling the revised Amsterdam criteria. Our data suggest a




A total of 33 colorectal tumours were obtained from HNPCC patients with germline
alterations in the MSH6 gene (n=10) and from HNPCC families negative for germline
mutations in the MMR genes MLH1, MSH2 or MSH6 (n=22). Two extracolonic tumours from
two of these patients were also analysed as well as 3 extracolonic tumours from 3 additional
patients (Table 1). Tumours were obtained from the University Hospital Groningen
(Groningen, The Netherlands), Sapporo Medical University (Sapporo, Japan) and also from
several different hospitals in Finland. Sample collection was carried out in accordance with
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the previously established ethical protocols from each one of the participating institutions, and
the respective ethics committees approved the study. Genomic DNA was extracted with
phenol-chloroform according to standard procedures. Microsatellite instability was analysed
according to the international criteria for the determination of microsatellite instability, using
various panels of dinucleotide and mononucleotide repeat sequences as previously
described.13 Accordingly, tumours were classified as MSI-H or MSI-low (MSI-L) when
showing high or low levels of instability, respectively.
Tumour samples had been analysed previously for germline mutations in the MLH1, MSH2
and MSH6 genes by several laboratory routines and mutations verified by automatic
sequencing. In some cases, large deletions of MLH1 and MSH2 were detected by Southern
blotting or using alternative strategies.14,15 Immunohistochemical stainings for MLH1 (clone
G168-728, BD Pharmingen, San Diego, CA, USA), MSH2 (clone FE11, Calbiochem, San
Diego, CA, USA), MSH6 (clone 44, Transduction Laboratories, Lexington, KY, USA),
PMS1 (sc-615, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and PMS2 (sc-618,
Santa Cruz Biotechnology Inc.) were also performed.
Mutational analysis of the BRAF-V600E hotspot.
The analysis of BRAF was performed by automatic sequencing. The fragment encompassing
exon 15 was amplified by PCR in all carcinoma samples. Primer sequences and PCR
conditions were based on those reported previously.1 Genomic DNA (25 - 100 ng) was
amplified by PCR using the following cycling conditions: 30 seconds at 94ºC, 30 seconds at
60ºC, and 45 seconds at 72ºC for 35 cycles. PCR products were purified and sequenced on an
ABI Prism 377 Automatic sequencer (Perkin-Elmer, Foster City, CA) using the ABI Prism
Dye Terminator Cycle Sequencing Kit (Perkin-Elmer).
Two sided Fisher’s exact test was used for statistical analysis.
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Table 1. Features of HNPCC tumours found negative for the BRAF-V600E mutation
Patient MMR1 Mutation Location MSI Age Criteria2
Y88 MSH6 truncating (3263insT) transverse MSI-H 38 -
Y701 MSH6 truncating (650insT) rectum MSI-H 53 -
Y7083 MSH6 truncating (2672delT;2674delT) descendent MSI-H 55 -
Y725 MSH6 truncating (650insT) left-sided4 MSI-H 83 +
Y1 MSH6 truncating (Glu1258X) rectum MSI-L 55 -
Y37 MSH6 truncating (650insT) descendent MSI-L 59 -
Y241 MSH6 missense (Ala355Val) descendent MSI-H 65 -
Y105 MSH6 missense (Ile725Met) transverse MSI-L 36 -
Y243 MSH6 missense (Gln522Arg) rectum MSI-L 43 -
Y319 MSH6 missense (Pro1087Ser) rectum MSI-L 39 -
Y194 - - rectum MSI-H 58 +
Y249 - - transverse MSI-H 48 +
CCH1 - - ascendent MSI-H 46 +
CCH2 - - cecum MSI-H 47 +
CCH3 - - descendent MSI-H 49 +
CCH4 - - transverse MSI-H 38 +
CCH5 - - cecum MSI-H 42 +
CCH6 - - descendent MSI-H 47 +
CCH7 - - ascendent MSI-H 31 +
CCH8 - - cecum MSI-H 45 +
CCH9 - - cecum MSI-H 43 -
CCH11 - - transverse MSI-H 50 -
CCH12 - - cecum MSI-H 46 -
CCH14 - - transverse MSI-H 48 -
CCH15 - - cecum MSI-H 55 -
CCH16 - - cecum MSI-H 44 -
CCF265 - - ascendent MSI-H 82 -
CCF910 - - cecum MSI-H 81 -
Y74 - - rectosigmoid MSI-L 48 +
Y168 - - sigmoid MSI-L 35 +
CCH10 - - ascendent MSI-L 62 -
CCH13 - - ascendent MSI-L 44 -
Other tumours
Y1 MSH6 truncating (Glu1258X) pyelum MSI-H 63 -
Y37 MSH6 truncating (650insT) endometrium MSI-L 65 -
Y605 MSH6 truncating (650insT) endometrium MSI-L 46 +
Y751 MSH6 truncating (650insT) duodenum MSI-L 51 -
Y77 - - duodenum MSI-H 54 +
1: Defective MMR gene. Negative cases do not show mutations in MLH1, MSH2 or MSH6 genes. 2:
Positive cases fulfil the Amsterdam criteria and negative cases are from families showing an HNPCC-like
pedigree in which at least one first degree relative is affected by an early onset colorectal cancer. 3: This
patient also showed a synchronous MSI-H tumour in the cecum that was positive for BRAF-V600E and




We have analysed 38 tumours from two different subsets of HNPCC (suspected) patients:
those that harbour an MSH6 germline defect, and patients from families fulfilling the clinical
criteria but in whom no MLH1, MSH2 or MSH6 germline mutations could be identified (see
Table 1). All patients belong to different families. As shown in Table 1, the analysed cases
either fulfilled the Amsterdam criteria or were positive for specific criteria from the Bethesda
guidelines (HNPCC-like).11,16,17 The indexed patients of these HNPCC-like families have
early onset colorectal cancer and at least a first-degree relative with a HNPCC-related
tumour.17
We have recently suggested the introduction of the BRAF-V600E mutation screening in the
molecular diagnostic protocols for HNPCC as a low-cost effective strategy that allows
simplifying the genetic testing of HNPCC patients.9 The reported absence of V600E
mutations in HNPCC cases that harbour germline mutations in the MLH1 and MSH2 genes,
predicted a potential use of BRAF as a pre-screening tool in HNPCC as only BRAF-V600E-
negative cases need to be screened for mutations in the MMR genes MLH1 and MSH2.4,8,9
Further, it suggests that BRAF mutations are not involved in HNPCC tumorigenesis, but are
restricted to the sporadic cases. However, it is unknown yet whether BRAF could be involved
in HNPCC tumours without germline mutations in MLH1 and MSH2. In fact, almost half of
the HNPCC families show no mutations in the MMR genes and about 5% of cases are due to
germline mutations of the MSH6 gene.7,10-12,18
To answer these questions, BRAF-V600E mutations were screened in 12 colon tumours
derived from patients from HNPCC families that fulfilled the Amsterdam criteria but did not
show germline mutations in MLH1, MSH2 or MSH6. In none of these tumours, the BRAF-
V600E mutations were identified. In all, 10 of these tumours were classified as MSI-H and
two as MSI-L, according to the international Bethesda criteria.13 An additional MSI-H tumour
from the duodenum of an HNPCC family positive for Amsterdam criteria was also found
negative for BRAF mutations. Furthermore, no mutations were detected in 10 colorectal
tumours, eight MSI-H and two MSI-L, respectively, from suspected HNPCC families not
fulfilling the Amsterdam criteria, but being positive for clinical criteria suggestive of familial
cancer. Also, we have extended our analysis to colon tumours, five MSI-H and five MSI-L,
from 10 HNPCC(like) families showing germline mutations in MSH6. Of these families, six
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proved to have truncating and four missense mutations of this gene (Table 1). Regarding these
families, one was positive for Amsterdam criteria and nine were suspected HNPCC,
according to the clinical criteria above described. We did not detect BRAF-V600E mutations
in these cases. Two additional tumours from the endometrium and pyelum from two patients
of these families, as well as two extracolonic tumours from the duodenum and endometrium
from two additional families showing germline truncating mutations in MSH6, were also
negative for BRAF mutations (Table 1).
Interestingly, in one of the analysed patients with a truncating MSH6 germline mutation, a
synchronous MSI-H colorectal cancer in the cecum was found positive for the BRAF-V600E
mutation. This tumour, however, showed an absence of MLH1 by immunohistochemistry
(IH) and hypermethylation of the MLH1 promoter. This finding is best explained by the
significant reported association of BRAF-V600E with the hypermethylation of MLH1 as seen
in a high frequency of sporadic tumours, a phenomenon not directly linked to the germline
mutation of MSH6.4,5
Overall, we did not detect significant BRAF-V600E mutations in any of these HNPCC
subsets, reinforcing the idea that BRAF is not involved in HNPCC tumorigenesis,
independently of the MMR gene defect and independent of the presence of high or low MSI
phenotypes. These results suggest a potential use of the BRAF mutation as a marker of
sporadic colorectal cancer.
Therefore, we suggest that detection of a positive BRAF-V600E mutation in a colorectal
cancer is most likely suggesting a sporadic origin of the disease and the absence of germline
alterations of MLH1, MSH2 and also of MSH6. Further, these findings might also have a
potential impact in the gene testing for HNPCC diagnostics.
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